Ms. Vanessa Slowey reports

TELYRX HOLDINGS INC. ANNOUNCES DTC ELIGIBILITY FOR U.S. TRADED SHARES

Telyrx Holdings Inc.'s subordinate voting shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (DTC). DTC eligibility is expected to simplify trading, improvement settlement efficiency, and enhance the liquidity and accessibility of Telyrx's shares for U.S. investors.

"Our mission is to make health care more accessible, and that same philosophy extends to how investors engage with Telyrx," said Vanessa Slowey, president and chief executive officer of Telyrx. "DTC eligibility removes barriers for U.S. investors, improves access to our shares and supports the next stage of our growth as we continue expanding our digital pharmacy platform."

DTC eligibility streamlines the trading process, making it more efficient for investors and brokers. As a subsidiary of the Depository Trust & Clearing Corp. (DTCC), DTC handles electronic clearing and settlement for publicly traded companies. With DTC eligibility, Telyrx's shares can now be traded across a wider network of brokerage firms, accelerating the settlement process and improving access for a broader range of investors.

About Telyrx Holdings Inc.

Telyrx is a technology-enabled health care and pharmacy services company operating a digital pharmacy platform connecting patients with independent, state-licensed providers to access over 450 everyday medications across 48 U.S. states and territories. The company fulfills prescriptions through its licensed retail pharmacies and offers fast, convenient delivery of medications directly to patients' doors.

We seek Safe Harbor.